Coya Therapeutics (NASDAQ:COYA) Upgraded to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen upgraded Coya Therapeutics from "sell" to "hold"; overall analyst mix is five Buys and one Sell with an average rating of "Moderate Buy" and an average price target of $16.00.
• Coya reported Q (Mar 16) EPS of ($0.34), missing the ($0.08) consensus while posting $3.96M in revenue (above $1.93M est.); the company has a deeply negative net margin (267.13%) and ROE (-62.76%), with sell-side forecasting -1.15 EPS for the year.
• Coya is a clinical-stage biotech targeting UNC-45A with lead programs COY-001 (fibrotic diseases) and COY-002 (solid tumors); the stock has a market cap of about $112M and a 12‑month range of $3.71–$7.75.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Saturday.

A number of other research firms also recently issued reports on COYA. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price objective on shares of Coya Therapeutics in a report on Monday, March 23rd. D. Boral Capital restated a "buy" rating and issued a $15.00 price objective on shares of Coya Therapeutics in a research note on Friday, April 10th. Weiss Ratings restated a "sell (d-)" rating on shares of Coya Therapeutics in a research note on Wednesday, January 21st. Finally, Chardan Capital restated a "buy" rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research note on Monday, March 16th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $16.00.

Coya Therapeutics Trading Up 6.7%

NASDAQ COYA opened at $4.78 on Friday. The company has a fifty day simple moving average of $4.53 and a 200 day simple moving average of $5.29. Coya Therapeutics has a 12-month low of $3.71 and a 12-month high of $7.75. The company has a market cap of $112.14 million, a P/E ratio of -3.76 and a beta of 0.51.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last posted its quarterly earnings results on Monday, March 16th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.26). The business had revenue of $3.96 million during the quarter, compared to analyst estimates of $1.93 million. Coya Therapeutics had a negative net margin of 267.13% and a negative return on equity of 62.76%. Sell-side analysts predict that Coya Therapeutics will post -1.15 EPS for the current year.

Hedge Funds Weigh In On Coya Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of COYA. JPMorgan Chase & Co. bought a new stake in Coya Therapeutics in the 3rd quarter worth about $28,000. CIBC Private Wealth Group LLC bought a new stake in shares of Coya Therapeutics during the 4th quarter valued at about $47,000. Occudo Quantitative Strategies LP bought a new stake in shares of Coya Therapeutics during the 4th quarter valued at about $66,000. Lantern Wealth Advisors LLC bought a new stake in shares of Coya Therapeutics during the 3rd quarter valued at about $66,000. Finally, Oppenheimer & Co. Inc. bought a new stake in shares of Coya Therapeutics during the 4th quarter valued at about $81,000. 39.75% of the stock is currently owned by institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc NASDAQ: COYA is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company's scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya's pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.